Search

Displaying results 1281 - 1290 of 10000 in total
  1. Drug

    Agalsidase alfa

    go.drugbank.com/drugs/DB15874
    ApprovedInvestigational

    [A220343] Agalsidase alfa was granted EMA approval on 3 August 2001.[L16413] … [A220228,A220233] Use of agalsidase beta has decreased in Europe, in favor of agalsidase alfa, after a contamination event in 2009.

    Synonyms: alpha-D-galactosidase, alpha-D-galactopyranosidaseProducts: REPLAGAL CONCENTRATE FOR SOLUTION FOR INFUSION 1 MG/ML
  2. Drug

    Kaolin

    go.drugbank.com/drugs/DB01575
    Approved

    Kaolin is used in ceramics, medicine, coated paper, as a food additive, in toothpaste, as a light diffusing material in white incandescent light bulbs, and in cosmetics.

    Mixtures: Donnagel-MB Sus, Donnagel-PG LiqProducts: Dr Pore Tightening PINK CLAY FACIAL MASK, Dr Pore Tightening GLACIAL CLAY FACIAL MASK
  3. Drug

    Anakinra

    go.drugbank.com/drugs/DB00026
    ApprovedInvestigational

    On November 14, 2001, it was approved by the FDA for the treatment of rheumatoid arthritis. … It was later approved for the treatment of NOMID and DIRA on December 21, 2012, and December 18, 2020, respectively.

    Products: Kıneret 100 mg/ 0.67 ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör, 7 ADET, Kıneret 100 mg/ 0.67 ml Enjeksiyonluk Çözelti İçeren Kullanıma Hazır Enjektör, 28 ADET
  4. Drug

    Pamidronic acid

    go.drugbank.com/drugs/DB00282
    ApprovedInvestigational

    [A203111] Pamidronic acid was first described in the literature in 1977. … [A203111] Pamidronic acid was granted FDA approval on 31 October 1991.[L13835]

    Products: Pamidronate Disodium Omega 6 mg/ml, Pamidronate Disodium Omega 9 mg/ml
  5. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.[L1332] … Ketamine is an NMDA receptor antagonist with a potent anesthetic effect.[A31869] It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories.

    Categories: N-Methylaspartate, agonists, N-Methylaspartate, antagonists & inhibitorsSynonyms: DL-ketamine
  6. Drug

    Lanadelumab

    go.drugbank.com/drugs/DB14597
    ApprovedInvestigational

    Lanadelumab, also known as DX-2930, is a human IgG1 monoclonal antibody designed for subcutaneous self-injection. … [A38676] Lanadelumab was approved for use in patients with hereditary angioedema by the FDA in August 2018,[L4537] followed by Health Canada in October 2018[L49226] and the EMA in November 2018.

    Categories: Drugs Used in Hereditary AngioedemaProducts: TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADET, TAKHZYRO 300 MG/2 ML ENJEKSİYONLUK ÇÖZELTİ İÇEREN KULLANIMA HAZIR ENJEKTÖR, 2 ADET
  7. Drug

    CIGB 2020 Vaccine

    go.drugbank.com/drugs/DB15808
    Experimental

    CIGB 2020 is a vaccine candidate administered nasally and sublingually, working to strengthen immunity in the areas administered. … As of July, 2020, a Randomized control clinical trial (RPCEC00000306) is underway to evaluate prophylaxis potential in suspected contacts of Covid-19 patients.

    Synonyms: CIGB 2020
  8. Drug

    Busulfan

    go.drugbank.com/drugs/DB01008
    ApprovedInvestigational

    According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen. … Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards.

    Products: MYLERAN 2 MG TABLET, 100 ADET, MYRAN TABLETS 2 mg
  9. Drug

    Medazepam

    go.drugbank.com/drugs/DB13437
    Investigational

    Mixtures: TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 20 ADET, TRANKO-BUSKAS 10 MG + 10 MG KAPLI TABLET, 40 ADETProducts: NOBRAL 10 MG KAPSÜL, 20 ADET, NOBRAL 10 MG KAPSÜL, 250 ADET
  10. Drug

    Etelcalcetide

    go.drugbank.com/drugs/DB12865
    ApprovedInvestigational

    Etelcalcetide was approved (trade name Parsabiv) for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis in February, 2017. … Etelcalcetide is a calcimimetic drug for the treatment of secondary hyperparathyroidism in patients undergoing hemodialysis.

    Products: PARSABIV SOLUTION FOR INJECTION 5 mg/mL, PARSABIV SOLUTION FOR INJECTION 2.5 mg/0.5 mL